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A B S T R A C T
Purpose: This study used an electronic practice management software in daily routine to gather long-
term disease and cost-of-illness (COI) data in patients with epilepsy in Germany.
Methods: Data on socio-economic status, course of epilepsy as well as direct and indirect costs were
recorded using practice software-based questionnaires.
Results: In 2011 we enrolled 359 patients (170 male (47.4%); mean age 50.5  20.7 years) in six neurological
practices. The majority of patients had been in long-term seizure remission for more than one year (n = 200,
55.7%) and in more than two-thirds the anti-epileptic drug (AED) monotherapy (n = 248, 69.1%) was used.
Levetiracetam (31%), lamotrigine (26%) and valproate (24%) were the drugs prescribed most frequently.
Total annual direct costs amounted to s1698 per patient with anticonvulsants (59.9% of total direct
costs) and hospitalization (30.0%) as the main cost factors. Of the patients enrolled 252 (70.2%) were of
working age and indirect annual costs due to absenteeism amounted to s745 per patient.
Potential cost-driving factors were seizure frequency and a recent diagnosis of epilepsy associated
with higher costs. Anticonvulsant treatment in patients aged 65 years and older was associated with
lower drug costs due to prescription of older AEDs.
Conclusion: We were able to demonstrate that electronic practice management software can easily be
used to perform long-term health economic evaluations with a bottom-up approach. The combination of
both physician- and patient-based electronic databases will facilitate performing less expensive studies,
but at the same time simplify large, prospective and multicentre clinical trials.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a common and chronic neurological disorder that
imposes a substantial burden on individuals and society as a
whole. The initial diagnosis of epilepsy is associated with costs of
diagnostic procedures and inpatient admission. In the further
clinical course the majority of patients require an anticonvulsant
treatment for an extended period of time and up to 30% of patientsserved.
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particularly important in patients with newly diagnosed and active
epilepsy as they account for a high proportion of total costs [2–5].
Given the growing resource utilization and limited amount of
healthcare resources, it has become essential to gather reliable cost
estimates as a scientiﬁc basis for resource allocation and health
policy decision making. In fact, this has become even more
important as the introduction of new antiepileptic drugs, the use of
generic medication, the marketing of brain stimulation devices and
the resurgence of new surgical treatment options can result in a
considerable increase in costs or a shift in the distribution of cost
components [6–10]. Furthermore, epilepsy is still strongly
associated with social stigma, reduced employment opportunities
and impaired quality of life for patients and their carers, resulting
in increased indirect as well as intangible costs [11–15].
For economic evaluations either a top-down or a bottom-up
approach is utilized to gather cost-of-illness (COI) data [16]. The
bottom-up approach is individual-related and preferred when
precise cost estimates are required for different subpopulations. It
allows epilepsy-speciﬁc costs and detailed data on socio-
economic and disease course to be gathered, however such
studies are time-consuming and costly as each patient has to be
interviewed in detail [17]. On the other hand, top-down studies
are useful for high-prevalence illnesses that are well represented
in national surveys or insurance databases. However they are
incompatible with the stratiﬁcation of cost by patient or disease
characteristics [17].
To date, previous German COI studies have used a bottom-up
approach, with detailed questionnaires, usually spanning over a
three-month period, providing information on trends and cost-
driving factors over time [3,18–20]. Due to time-consuming and
labour-intensive implementation of such studies they cannot be
easily repeated or performed over long periods. Thus, the objective
of this bottom-up evaluation was to use an electronic practice
management software in daily routine to omit the labour-intensive
paper–pencil questionnaires, but to gather, simultaneously,
reliable, long-term disease and COI data in patients with epilepsy.
2. Patients and methods
2.1. Study setting and design
The evaluation was performed at six neurological practices
providing outpatient care throughout Germany in the cities of
Alzenau (18,491 inhabitants), Bielefeld (327,199), Dresden
(517,765), Gru¨nstadt (13,069), Neukirchen-Vluyn (27,689) and
Stuttgart (591,015), population data as of year 2011 (www.
destatis.de).
The study population consisted of consecutive outpatients, 18
years of age or older, with an established diagnosis of epilepsy, who
gave informed consent to electronic clinical data processing and
evaluation. The diagnosis was based on the deﬁnitions proposed by
the International League Against Epilepsy and the International
Bureau for Epilepsy [21]. The electronic data collection was
established in 2009 and patients were evaluated if a full data set
was available for the evaluation period between 1st January 2011
and 31st December 2011. Patients were excluded when the
diagnosis of epilepsy could not be determined without doubt.
2.2. Patients and cost assessment
Data on the epilepsy syndrome, concomitant diseases, MRI and
EEG ﬁndings, socioeconomic status, current antiepileptic drugs
(AED) and current seizure frequency were provided by the treating
neurologist and entered into an electronic practice management
software. For that purpose the practice management software wasequipped with the modular designed electronic expert system EPI-
Scout1 (epilepsy scout). The EPI-Scout1 software (Desitin
Arzneimittel GmbH, Hamburg; Medomus Technologien & Services
GmbH, Cologne, Germany; www.medomus.de/technologien/
software/episcout.php) supports the neurologist to orient themself
to the evidence-based guidelines for the diagnosis and the
treatment of patients with epilepsy and offers the possibility to
document case-related clinical action, either for exchange with
cooperation partners or towards payers. The software was
developed in collaboration with the Department of Epileptology,
University of Bonn and a working group of BVDN and BDN (Federal
Associations of German Neurologists) [22].
At each visit the patients were asked by the treating neurologist
about epilepsy-related direct and indirect costs. To facilitate the
survey only established main direct cost components, including
inpatient hospital and rehabilitation care, neurological outpatient
service and drug costs due to epilepsy, were recorded and
evaluated according to German recommendations for performing
health economic evaluations [23–25]. The aim of this evaluation
was to calculate the genuine costs due to epilepsy and not costs
that may be triggered by other diseases not related to epilepsy.
Therefore, patients were asked in detail whether or not the
medication, service or resource were used speciﬁcally for epilepsy.
The costs of formal and informal care are based on the three
nursing care levels (Pﬂegestufen) approved to the patient by the
statutory long-term care insurance (Pﬂegeversicherung, PV).
Former studies [18,19] indicated that nursing costs were mainly
not related to the epilepsy but to a handicap caused by the
underlying disease, such as stroke, dementia or cancer. Therefore,
we did not considered these nursing costs as due to epilepsy in this
evaluation.
The evaluation of costs was performed by means of a bottom-up
approach from the perspective of the statutory health insurance
(Gesetzliche Krankenversicherung, GKV). Averaged drug costs
were obtained from prescription reports [26]. Costs for inpatient
care (hospitalization and rehabilitation) were calculated based on
daily charges and the German Diagnosis Related Groups (2011,
G-DRG; www.g-drg.de). The charges for outpatient care were
obtained from the ofﬁcial German doctors’ fee scale (Einheitlicher
Bewertungsmaßstab, EBM) [27]. Other direct costs as laboratory
investigations of imaging were not evaluated in this study. Indirect
costs for lost productivity due to days off were evaluated using the
human capital approach for patients younger than 65 years.
According to the Federal Statistical Ofﬁce (www.vgrdl.de) the
mean gross income was s36,213 in 2011. All costs were calculated
for the evaluation period of one year and are provided in 2011 Euro
(s). For further details of the cost calculations, see previous studies
[3,28].
2.3. Data entry and statistical analysis
Data entry was performed by each neurologist using the
electronic practice management and EPI-Scout1 software. For
further evaluation and processing the data was exported and
anonymized by an independent company to comply with data
protection regulations [22].
Statistical analyses were performed using IBM SPSS Statistics 21
(SPSS Inc., Chicago, IL, USA). Cost data are presented as mean
 standard deviation (SD), minimum, maximum and median or
percentages where appropriate. In addition, 95% conﬁdence intervals
(C.I.) are provided using the bootstrap method according to the bias-
corrected accelerated (bca) approach, taking into account the fact that
most cost variables are right-skewed [29]. Comparisons between
groups were performed using the Mann–Whitney test or Kruskal–
Wallis test. When appropriate, post hoc comparisons (Holm–Bonfer-
roni) were reported and p-values were corrected.
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3.1. Clinical and sociodemographic characteristics
During the study period 359 (170 male (47.4%); 189 female)
consecutive outpatients treated for epilepsy by neurologists in
outpatient ofﬁces were recruited. The mean age was 50.5  20.7
years (range 18–99 years). Half of the patients suffered from focal
epilepsy (n = 186, 51.8%) the remaining from idiopathic generalized
epilepsies (n = 56, 15.6%) and other or unknown epilepsy syndromes
(n = 117, 32.6%). The majority of patients were in long-term seizure
remission for more than one year (n = 200, 55.7%) and in more than
two-thirds AED monotherapy (n = 248, 69.1%) was used. Table 1
shows detailed clinical characteristics. None of the surveyed patients
died during the study period. Further socio-demographic character-
istics in terms of marital status, residential situation, employment
status, disability level, nursing needs and reported difﬁculties in daily
life are presented in Table 2.
3.2. Direct and indirect costs
Table 3 shows the epilepsy-speciﬁc costs of patients during a
one-year evaluation period in 2011. Total annual direct costs
amounted to s1698 (SD s2247, range s52–15,377) per patient,
with anticonvulsants (59.9% of total direct costs) and hospitaliza-
tion (30.0%) as the main cost factors. Anticonvulsant monotherapy
was associated with mean costs of s651 (n = 248) with
levetiracetam (mean annual costs s1507, n = 59), lamotrigine
(s257, n = 48), valproate (s203; n = 42), carbamazepine (s140;
n = 24) and oxcarbazepine (s759; n = 19) as the main ﬁve
monotherapies of choice.
During the evaluation period in 2011 ﬁfty patients (13.9%) were
admitted to a hospital for 1–29 days (mean hospital stay 8.1 days)
with mean costs of s3650 per admission. Nine patients (2.5%)
were admitted for rehabilitation to a hospital for 9–48 days (mean
hospital stay 22.4 days) with mean costs of s3973 per admission.
The estimate of mean indirect costs was based on patients with
a working age of below 65 years. This amounted to 252 patientsTable 1
Clinical characteristics.
Age in years* 
Disease duration in years 
Anticonvulsants Mean number of AEDsa
Monotherapy 
2 AEDs 
>3 AEDs 
Epilepsy syndrome 
Focal epilepsy 
Idiopathic generalized epilepsy 
Unclassiﬁed or other syndromes 
Seizure frequency 
Seizure remission > 1 year 
Active epilepsy 
1 seizure/year 
2–10 seizures/year 
>10 seizures/year 
n.a. 
a Mean  standard deviation.(70.2%) of working age, and indirect annual costs due to days off
amounted to s745 (SD s3587) per patient. Thirty patients (11.9%)
had to take days off due to seizures. The mean annual duration of
work absenteeism was 4.8  24.6 days (range: 0–230).
Table 4 presents each cost factor for patients in seizure
remission of more than one year and for patients with active
epilepsy.
3.3. Prescription patterns and medication costs
Costs and daily dosages of different AEDs are listed in Table 5.
The mean AED costs were s1017 (SD s1224, range s23–8334) per
one year. Levetiracetam (31%), lamotrigine (26%) and valproate
(24%) were the drugs prescribed most frequently. Sixty-nine per
cent of the patients received AED in monotherapy. Zonisamide,
lacosamide and levetiracetam were associated with the highest
costs, along with infrequently prescribed AEDs such as eslicarba-
zepine acetate (n = 2), retigabine (n = 1) or vigabatrin (n = 1). The
proportion of enzyme-inducing anticonvulsants was 18.1% (89 out
of 491 prescribed drugs). Likewise the share of so-called ‘older’
AEDs was 35.8% (176/491).
3.4. Cost-driving factors
Potential cost-driving factors were identiﬁed by univariate
analysis as well as post hoc tests and are presented in Table 6. We
found a positive correlation of seizure frequency with increased
medication, hospitalization, and direct and indirect costs. Epilepsy
syndrome and gender did not inﬂuence costs in this analysis. A
recent diagnosis of epilepsy in the ﬁrst two years correlates with
higher hospitalization and indirect costs than an established
diagnosis of more than three years. Analysis of total direct
(p = 0.057), AED (p = 0.087), hospital (p = 0.371) and indirect
(p = 0.577) costs did not reveal a signiﬁcant correlation with the
treating neurologist.
Anticonvulsant treatment in patients aged 65 years and older
was associated with lower drug costs. Elderly patients aged 65 years
and older were treated mainly with monotherapy (92/107; 86%) andn = 359
50.5  20.7
Range 18–99
% (n)
0–2 years 23.4 (84)
3–5 years 10.9 (39)
5–10 years 19.2 (69)
>10 years 46.5 (167)
1.4  0.6
% (n)
69.1 (248)
25.1 (90)
5.8 (21)
% (n)
51.8 (186)
15.6 (56)
32.6 (117)
% (n)
55.7 (200)
43.2 (155)
14.4 (51)
19.9 (73)
9.0 (31)
1.1 (4)
Table 2
Detailed socio-demographic parameters.
All patients n = 359
% (n)
Marital status
Married/living in relationship 48.7 (175)
Single 37.6 (135)
Divorced 7.0 (25)
Widowed 6.7 (24)
Residential status
Lives with partner/family 70.8 (254)
Lives alone 13.1 (47)
Assisted living 1.9 (7)
Nursing home or clinic 14.2 (51)
Employment situation
Employed 42.7 (157)
Ongoing school education 2.2 (8)
Vocational training 5.3 (19)
Unemployed 15.3 (55)
Early and old-age retirement 33.4 (120)
Activities of daily life
No problems 54.3 (195)
Mild impairment 28.4 (102)
Severe impairment 17.3 (62)
Nursing demand
None 76.6 (275)
Nursing care level 1a 8.6 (31)
Nursing care level 2a 5.8 (21)
Nursing care level 3a 8.6 (31)
n.a. 0.3 (1)
Disability level
None 48.5 (174)
0–50% 13.1 (47)
60–100% 38.4 (138)
a According to German statutory long-term care insurance.
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annual costs s1462, n = 33), carbamazepine (s104; n = 16);
phenytoin (s66; n = 14), gabapentin (s374; n = 13) and valproate
(s220, n = 13) were the ﬁve most prescribed drugs in the elderly.
4. Discussion
This study is the ﬁrst evaluation to gather annual disease and
COI data in patients with epilepsy using an electronic practice
management software in daily routine. We were able to present
recent data in 2011 prices and tariffs and conﬁrm previous studies
showing the difference in health-care utilization by patients inTable 3
Annual direct and indirect costs in Euro (year 2011 values).
Direct cost components Mean SD % of total
direct costs
Hospitalization 510 1622 30.0% 
Rehabilitation 101 736 5.9% 
Outpatient neurological care 72 53 4.2% 
Anticonvulsants – all patients 1017 1224 59.9% 
Monotherapy (n = 248, 69.1%) 651 791 
2 AEDs (n = 90, 25.1%) 1585 1321 
3 AEDs (n = 21, 5.8%) 2916 2109 
TOTAL DIRECT COSTS 1698 2247 100% 
INDIRECT COSTS (<65 y) Mean SD 
Days off due to seizures (n = 252) 745 3587 
SD: standard deviation, 95% CI: 95% conﬁdence interval using the bootstrap bias correseizure remission and those with active epilepsy. Furthermore we
were able to demonstrate high hospitalization and indirect costs
due to days off in the ﬁrst two years upon diagnosis of epilepsy.
This is likely due to inclusion of patients with newly diagnosed
epilepsy causing high inpatient and indirect costs upon diagnosis,
which is in line with previous long-term studies [30,31].
Comparison of the presented prescription patterns with previous
German evaluations from 2003 [3], 2008 [19] and 2009 [32],
demonstrates an increase in the prescription of ‘newer’ drugs and
decrease in prescription of enzyme-inducing anticonvulsants.
This study was able to include a large subgroup (n = 107) of
elderly patients, which tend to be neglected in ﬁeld studies.
Interestingly, anticonvulsant treatment in the elderly > 65 years
was associated with lower costs as compared to patients aged
18–65 years. This subgroup is mainly treated with monotherapy
(86%) as compared to patients aged 18–65 years with 62% on
monotherapy (156/252); however, the proportion of seizure-free
patients is similar, with 56% and 57% in both groups. Older AEDs
such as carbamazepine, phenytoin and valproate are still widely
used, as well as gabapentin which was formerly considered as the
drug of choice in the elderly. This is in keeping with evaluations on
a national level which still show a predominance of older AEDs
such as carbamazepine, valproate, phenytoin and primidone being
prescribed to the elderly [32]. This could be regarded as
inappropriate treatment in this age group. However, a recent
study of elderly epilepsy patients showed that elderly with chronic
epilepsy seem to continue their treatment with phenytoin,
carbamazepine and valproate, while a large proportion of patients
are on lamotrigine and levetiracetam [33]. In contrast, those
elderly with late-onset epilepsy are often started on levetiracetam
or gabapentin [33]. Probably, in the course of time, mainly newer
AEDs will be prescribed to the elderly with both chronic and late-
onset epilepsies. On the other hand elderly patients caused higher
costs for hospitalization possibly reﬂecting the need of admissions
in the presence of frailty and other comorbidities.
The direct medical costs in our study were mainly caused by
AEDs and hospitalization. The increasing utilization of newer and
cost-intensive AEDs, such as levetiracetam is in line with recent
studies conﬁrming this trend towards an increased usage of newer
AEDs [31–34]. This ﬁnding explains the high costs for antic-
onvulsants and conﬁrms other recent COI studies [18,34,35], which
showed that AEDs were becoming the main contributor to direct
costs. However, inpatient costs are still a major cost component
and studies with a top-down approach from Denmark [36] and the
United States [37,38] proved hospitalization to be the major direct
cost factor. Possibly, cost-intensive patients with status epilepticus
[39,40] and patients undergoing video-EEG monitoring or epilepsyMinimum Median Maximum Bootstrap 95% CI
– – 13.091 352 681
– – 8498 36 182
29 58 288 67 79
23 516 8334 887 1130
23 309 5055 557 755
107 1304 6015 1337 1841
453 2662 8334 2092 3880
52 716 15,377 1474 1907
Minimum Median Maximum Bootstrap 95% CI
– – 29.763 391 1.169
cted and accelerated method.
Table 4
Direct and indirect costs stratiﬁed according to seizure status.
Cost components Seizure free > 1 year (n = 200) 95% CI Active epilepsy (n = 155) 95% CI p-Value
Mean annual
costs
SD Mean annual costs SD
Hospitalization s172 948 59; 316 s932 2123 636; 1263 <0.001
Rehabilitation s56 628 0; 154 s160 855 54; 294 0.037
Outpatient neurological care s65 47 59; 72 s82 59 73; 93 0.003
Anticonvulsants s825 990 694; 952 s1.237 1415 1024; 1473 0.001
TOTAL DIRECT COSTS s1.117 1538 916; 1337 s2.404 2734 2029; 2830 <0.001
INDIRECT COSTS (<65 y) Seizure free > 1 year
(n = 139)
95% CI Active epilepsy (n = 109) 95% CI p-Value
Mean annual
costs
SD Mean annual costs SD
Days off due to seizures (n = 252) s456 3062 74; 916 s1.125 4165 443; 1930 <0.001
Table 5
Annual costs of anticonvulsants and prescription patterns (n = 359, year 2011 values).
n Mean daily
dose in mg  SDa
Minimum
in mg
Median
in mg
Maximum
in mg
Mean annual costs
in Euro  SDa
Levetiracetam (30.6%) 110 1434  737 500 1000 3500 1619  832
Lamotrigine (26.2%) 94 235  163 25 200 800 261  180
Valproate (24.2%) 87 1248  722 300 1000 4200 231  134
Carbamazepine (13.1%) 47 761  373 100 800 1600 164  80
Oxcarbazepine (10.9%) 39 1426  856 75 1200 3600 817  491
Phenytoin (6.4%) 23 226  78 100 200 400 69  24
Topiramat (5.3%) 19 183  128 25 150 500 1242  871
Gabapentin (4.7%) 17 1000  412 600 900 2400 430  177
Primidon (3.3%) 12 367  220 100 350 750 85  51
Lacosamide (2.5%) 9 333  71 200 300 400 2031  431
Phenobarbital (1.9%) 7 79  42 25 75 150 135  72
Zonisamide (1.9%) 7 329  170 100 400 500 2351  1219
other AEDsc (5.6%) 20
Percentage of enzyme-inducing AEDsb 18.1%
Percentage of ‘old’ AEDsb 35.8%
a Mean  standard deviation.
b Enzyme-inducing AEDs: carbamazepine, phenobarbital, primidon, phenytoin; ‘old’ AEDs: valproate, carbamazepine, phenobarbital, primidon, phenytoin.
c Other prescribed AEDs were pregabalin (n = 6), clobazame (n = 3), sultiame (n = 3), eslicarbazepinacetate (n = 2) ethosuximide (n = 2), tiagabine (n = 2), retigabine (n = 1)
and vigabatrin (n = 1).
Table 6
Cost and cost components stratiﬁed by potential cost-driving factors.
n Total direct
costs
SD p-Valuea AED
costs
SD p-Valuea Hospitalization
costs
SD p-Valuea n Indirect
costs
SD p-Valuea
Gender 0.097 0.032 0.527 0.603
Female 189 s1.693 2510 s954 1315 s533 1786 130 s743 3598
Male 170 s1.704 1921 s1.088 1115 s486 1421 122 s747 3591
Age 0.586 0.004b 0.032 0.790
18–40 years 128 s1.790 2272 s1.165 1411 s409 1252 128 s909 4369
41–65 years 124 s1.502 1618 s1.154 1290 s193 703 124 s577 2549
>65 years 107 s1.817 2787 s683 766 s1.000 2460 – – –
Disease duration 0.107 0.118 <0.001b 0.001b
0–2 years 84 s2.254 2870 s852 976 s1.188 2531 38 s2.406 7100
3–5 years 39 s1.095 1401 s710 757 s313 999 21 s132 413
5–10 years 69 s1.569 2014 s1.076 1243 s281 1143 50 s565 2629
>10 years 167 s1.613 2101 s1.148 1392 s310 1181 143 s463 2543
Epilepsy syndrome 0.057 0.188 0.381 0.814
Focal epilepsy 186 s1.900 2492 s1.047 1170 s672 1960 111 s306 1765
Idiopathic generalized
epilepsy
56 s1.322 1744 s981 1472 s153 533 53 s809 4219
Unclassiﬁed or other
syndromes
117 s1.558 2022 s988 1189 s424 1318 88 s1.269 4710
Seizure frequency <0.001b 0.001b <0.001b 0.001b
Seizure remission > 1 year 200 s1.117 1538 s825 990 s172 948 139 s456 3062
1 seizure/year 51 s2.534 3307 s901 928 s1.452 2806 29 s1.326 5222
2–10 seizures/year 73 s2.054 2179 s1.172 1165 s545 1306 57 s1.077 3770
>10 seizures/year 31 s3.013 2835 s1.944 2207 s976 2236 23 s987 3749
a Mann–Whitney or Kruskal–Wallis test (two-sided), SD: standard deviation.
b Signiﬁcant p-values after Holm–Bonferroni correction.
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only. Studies with a top-down approach have the advantage of
including all patients with epilepsy, irrespective of their ability to
participate in ﬁeld studies. However, it remains difﬁcult to
distinguish between epilepsy-speciﬁc costs and costs for comor-
bidities. In both studies from the United States [37,38] epilepsy-
related costs for AEDs and claims for epilepsy or convulsions
diagnoses accounted for only 32–46% of excess direct costs.
Overall, these cost estimates rather represent the average costs of
patients with epilepsy than the epilepsy-speciﬁc costs. Overall, the
ongoing shift in direct cost components in our and other studies
suggests that the costs of AEDs and hospitalization are continu-
ously changing and depend on the research setting and health
systems. On the one hand, the introduction of generic formulations
will surely be associated with further decreasing AED costs. This is
especially true for levetiracetam and lamotrigine, which are the
drugs of choice in our study. On the other hand, the development of
hospitalization costs is rather difﬁcult to forecast and will need
further evaluation.
We were able to demonstrate that electronic practice
management software can easily be used to perform long-term
health economic evaluations with a bottom-up approach. By that
means time-consuming and labour-intensive implementation of
ﬁeld studies can be avoided while repeated or long-term
evaluations are facilitated. Further use of electronic seizure
diaries with direct information from the patient may allow the
assessment of the clinical course in individual patients to be
improved. Electronic seizure diaries have been proved to be reliable
tools for clinical [41,42] and health economic evaluations [43]. The
combination of both physician- and patient-based electronic
databases will facilitate performing less expensive studies, but at
the same time simplify large, prospective and multicentre clinical
trials.
Despite the careful study design, this COI study suffers from
certain limitations inherent to such investigations. In order to
collect data regarding several direct cost components and indirect
costs, the patients were asked about resource consumption at each
visit and the possibility of incomplete patient recall cannot be
excluded, which could have resulted in an underestimation of costs
and a large variability in cost estimates. Also we did not record in
detail all possible costs due to epilepsy-related comorbities (e.g.
depression, osteoporosis) or AED use [44], unless they resulted in a
hospital admission. Due to recruitment from neurologists in
private practice there might be a bias towards a referral population
leading to higher costs. Further limitations of our study were due to
the calculation of indirect costs using the human capital approach.
In the current situation of underemployment in the general
population, indirect costs may not exactly reﬂect the burden on
society and may be overestimated [45]. However, due to the
limitations of the friction cost approach [46], we retained the
human capital approach, which is in accordance with the German
and international recommendations for performing health eco-
nomic evaluations [25].
5. Conclusions
We were able to demonstrate that electronic practice manage-
ment software can easily be used to perform long-term health
economic evaluations with a bottom-up approach.
Future studies should evaluate the development of direct cost
components with a focus on hospitalization and anticonvulsants.
From the societal perspective, major efforts should focus on the
reduction of seizures for maintaining quality of care and reducing
the need for hospitalization in epilepsy patients, thus improving
the life quality of patients.Conﬂict of interest statement
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